अApnaFunda
Menu

KRISHNA INSTITUTE OF MED SCI (KIMS)

Health Services · Hospital/Nursing Management · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.27 / 100
Profitability 26Growth 51Balance sheet 5
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.46 / 100
Price 34Earnings 15FII/DII 88
Compare withAPOLLO HOSPITALS ENTERPRISES LMAX HEALTHCARE INSTITUTEASTER DM QUALITY CARE

Share price

Closing priceAdjusted for splits and bonus issues.

₹721.65 latest close · −15.2% over the last 90 sessions

₹700₹800Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹700₹800Jul 3Sep 4Nov 9

₹721.65 month-end · +5.3% over 12 months

₹600₹700₹800Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹600₹700₹800Nov '25May '26Nov '26

₹721.65 month-end · +84.5% over 3 years

₹400₹600₹800Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹400₹600₹800Nov '23May '25Nov '26

₹721.65 month-end · +281.0% since Jun '21

₹200₹400₹600₹800Jun '21Jul '22Aug '23Sep '24Oct '25Nov '26 ₹200₹400₹600₹800Jun '21Mar '24Nov '26

52-week range ₹575.80 to ₹858.00 · 1-year volatility 31.7%

Was the rally earned?

+5%share price, 1 yearMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 72.9x to 142.9x); per-share earnings took off 64 points.
  • The share count fell 11%.
Net profit growth: −75 pts. Points of the price return explained by net profit growing (or shrinking).−75 ptsNet profit growthP/E change: +69 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+69 ptsP/E changeShare count change: +12 pts. Points of the price return explained by the share count changing. More shares count against the price.+12 ptsShare count changeShare price: +5%+5%Share priceNet profit growth: −75 pts. Points of the price return explained by net profit growing (or shrinking).−75ProfitP/E change: +69 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+69P/EShare count change: +12 pts. Points of the price return explained by the share count changing. More shares count against the price.+12SharesShare price: +5%+5%Share price
Net profit growth-75 ptsNet profit fell about 52%, which lowers the price.
P/E change+69 ptsThe P/E rose from 72.9x to 142.9x, which lifts the price.
Share count change+12 ptsShare count fell 11%, which lifts the price.
+85%share price, 3 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 46.5x to 142.9x); per-share earnings took off 70 points.
  • The share count fell 12%.
Net profit growth: −88 pts. Points of the price return explained by net profit growing (or shrinking).−88 ptsNet profit growthP/E change: +155 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+155 ptsP/E changeShare count change: +17 pts. Points of the price return explained by the share count changing. More shares count against the price.+17 ptsShare count changeShare price: +85%+85%Share priceNet profit growth: −88 pts. Points of the price return explained by net profit growing (or shrinking).−88ProfitP/E change: +155 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+155P/EShare count change: +17 pts. Points of the price return explained by the share count changing. More shares count against the price.+17SharesShare price: +85%+85%Share price
Net profit growth-88 ptsNet profit fell about 47%, which lowers the price.
P/E change+155 ptsThe P/E rose from 46.5x to 142.9x, which lifts the price.
Share count change+17 ptsShare count fell 12%, which lifts the price.
+191%share price, 5 yearsMultiple-driven

Partly.

  • Most of the rise came from investors paying a higher multiple (P/E 47.8x to 142.9x); per-share earnings took off 5 points.
  • The share count fell 3%.
Net profit growth: −10 pts. Points of the price return explained by net profit growing (or shrinking).−10 ptsNet profit growthP/E change: +196 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+196 ptsP/E changeShare count change: +5 pts. Points of the price return explained by the share count changing. More shares count against the price.+5 ptsShare count changeShare price: +191%+191%Share priceNet profit growth: −10 pts. Points of the price return explained by net profit growing (or shrinking).−10ProfitP/E change: +196 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+196P/EShare count change: +5 pts. Points of the price return explained by the share count changing. More shares count against the price.+5SharesShare price: +191%+191%Share price
Net profit growth-10 ptsNet profit fell about 5%, which lowers the price.
P/E change+196 ptsThe P/E rose from 47.8x to 142.9x, which lifts the price.
Share count change+5 ptsShare count fell 3%, which lifts the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with APOLLO HOSPITALS ENTERPRISES L

How rough has the ride been?

Maximum drawdown-26.3%recovered 2026-06
1-year volatility31.7%annualised
Beta vs sector index0.663-year daily, correlation 0.39
Volume spikes0last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−10%−20%20222023202420252026−26.3% 0%−10%−20%202220242026−26.3%
Largest drawdowns

-26.3% (2025-07 peak to 2026-01 low, recovered 2026-06)

-25.1% (2022-01 peak to 2022-06 low, recovered 2022-09)

-23.1% (2025-01 peak to 2025-03 low, recovered 2025-04)

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

142.9xP/E todayNear its historic high
Against its own history98th percentile
CheapestMedian 52.6xDearest

Usual range 36.1x to 95.0x since 2021-06.

Against Health Services142.9x vs 50.9x
This company
142.9x
Sector median
50.9x

181% above the Health Services median.

28.5x68.2x108.0x147.8xJun '21Jul '22Aug '23Sep '24Oct '25Nov '2628.5x68.2x108.0x147.8xJun '21Apr '23Feb '25Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Services median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Services median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Services is valued

Where does it rank among Health Services peers?

Each cell is the company's percentile rank among its Health Services peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE19th▼ 33 pts vs a year ago
  • Op. margin33rd▼ 13 pts vs a year ago
  • Revenue growth79thflat vs a year ago
  • EPS growth7th▼ 49 pts vs a year ago
  • Debt/equity ↓4thflat vs a year ago
  • Cash cycle ↓24th▼ 6 pts vs a year ago
  • P/E ↓9th▼ 25 pts vs a year ago
  • 12M momentum63rdflat vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Services sector page Watch it move against Health Services in the Observatory

What is the price implying?

~33%annual earnings growth implied by the price

At a P/E of 81.4x, the price would imply about 32.6%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Services The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹721.65
P/E
142.9x
ROCE
10.0%
Market Cap
₹30301 cr
Revenue (TTM)
₹4214 cr
P/S
7.2x
P/B
13.5x
ROE
9.4%
Operating Margin
19.0%
Debt / Equity
1.9x
Promoter Holding
32.5%
12M Momentum
5.3%

52-week range

₹575.80₹858.00
52% of the way from its 52-week low to its high

Price risk

1Y volatility
31.7%
Beta vs sector
1-year daily
0.88

Balance sheet & cash

Interest cover
operating profit ÷ interest
2.1x
Cash from profit, 3Y
operating cash flow ÷ net profit
1.63x
Share count, 1Y
unchanged

Are profits backed by cash?

5 of 6checks within range1 beyond a threshold
Other income reliance10%Within range

Other income as a share of pre-tax profit (trailing twelve months): 9.7%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate26%Within range

Median quarterly effective tax rate over about 2.5 years: 26.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion1.63xWithin range

Operating cash flow divided by net profit over the last three fiscal years: 1.63x (cash from operations ₹1,614 cr, net profit ₹993 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow1 of 5 yrsBeyond threshold

Fiscal years with positive free cash flow in the last 5: 1. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+9 daysWithin range

Debtor days are above the median of the previous three fiscal years by 9 days (52 vs 43). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress11% of fixed assetsWithin range

Capital work-in-progress is 11% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days—Not enough data

Not enough reported data to compute this.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, promoters trimmed 6.4 pts; FIIs added 0.5 pts.
  • The number of shareholders rose from 66,957 to 94,730 (+41%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters38.9%32.5%-6.4 pts
FIIs14.2%14.8%+0.5 pts
DIIs34.8%34.4%-0.4 pts
Public and others12.1%18.3%+6.2 pts

Number of shareholders

94,730shareholders+41% since Sep '23
67k81k95k1.1L Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 66,957
Dec '23: 71,014
Mar '24: 69,092
Jun '24: 69,063
Sep '24: 77,617
Dec '24: 95,468
Mar '25: 1.0 lakh
Jun '25: 1.1 lakh
Sep '25: 1.0 lakh
Dec '25: 1.0 lakh
Mar '26: 93,333
Jun '26: 94,730
 67k81k95k1.1L Sep '23Sep '24Sep '25Jun '26
Sep '23: 66,957
Dec '23: 71,014
Mar '24: 69,092
Jun '24: 69,063
Sep '24: 77,617
Dec '24: 95,468
Mar '25: 1.0 lakh
Jun '25: 1.1 lakh
Sep '25: 1.0 lakh
Dec '25: 1.0 lakh
Mar '26: 93,333
Jun '26: 94,730

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

−9.2%typical 12-month return vs the marketBelow the base rate
  • We found 50 past situations where a non-financial company looked like KRISHNA INSTITUTE OF MED SCI today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −30% to +11% vs the market, against −5% for all non-financial companies in the same months.
  • The analogs' median sat below that base rate (gap −4.4%, 80% range −13.1% to −1.6%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
ADANIGREEN · Apr 2024: −50.7% vs market
SIGNATURE · Jun 2025: −40.4% vs market
HNDFDS · Feb 2023: −40.0% vs market
RAMCOCEM · Jun 2023: −38.2% vs market
JUBLFOOD · May 2025: −36.2% vs market
HESTERBIO · Jul 2024: −33.6% vs market
SHOPERSTOP · Jul 2023: −33.6% vs market
NEOGEN · Jun 2023: −32.8% vs market
HATSUN · Oct 2021: −31.0% vs market
MHRIL · Aug 2023: −30.7% vs market
GODREJPROP · Jul 2024: −30.6% vs market
SAPPHIRE · May 2023: −30.5% vs market
WESTLIFE · Sep 2023: −30.4% vs market
VIPIND · Dec 2022: −29.6% vs market
JSWENERGY · Aug 2024: −25.5% vs market
ERIS · Oct 2025: −23.2% vs market
BATAINDIA · Jul 2022: −22.8% vs market
UPL · Feb 2020: −20.6% vs market
ARVINDFASN · Mar 2024: −20.5% vs market
GODREJIND · Dec 2024: −18.6% vs market
CENTURYPLY · Sep 2025: −16.6% vs market
DEVYANI · Dec 2022: −15.6% vs market
MOTILALOFS · Jul 2020: −11.7% vs market
JKCEMENT · Jun 2023: −11.4% vs market
ADANIENT · Jun 2022: −9.2% vs market
DALBHARAT · Feb 2021: −9.1% vs market
BLUEDART · Jan 2022: −8.2% vs market
NH · May 2020: −7.7% vs market
CHALET · Feb 2025: −7.1% vs market
LEMONTREE · Mar 2024: −5.1% vs market
BHARATFORG · Sep 2023: −4.3% vs market
VBL · Jan 2020: −1.6% vs market
BRIGADE · Feb 2024: −1.4% vs market
RKFORGE · Oct 2021: +1.4% vs market
ASTERDM · Oct 2025: +6.2% vs market
BIOCON · Sep 2025: +8.0% vs market
TVSMOTOR · Mar 2024: +8.5% vs market
ULTRACEMCO · Apr 2020: +11.2% vs market
ASAHIINDIA · Sep 2025: +11.4% vs market
ANURAS · Oct 2025: +12.5% vs market
TORNTPHARM · Jan 2020: +13.4% vs market
HCG · Jun 2025: +14.4% vs market
BHARTIARTL · Jul 2022: +14.4% vs market
APOLLOHOSP · Feb 2021: +30.8% vs market
PHOENIXLTD · Mar 2023: +44.0% vs market
NYKAA · Jun 2025: +48.9% vs market
CRAFTSMAN · Jun 2025: +69.5% vs market
YASHO · Jul 2025: +91.1% vs market
TRENT · Sep 2023: +150.9% vs market
ADANIENSOL · Dec 2020: +194.8% vs market
Similar setups −9.2%All companies −4.8%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 2 beyond the range shown, drawn at the edge

Similar setups' median
−9.2%
All companies' median
−4.8%
Beat the market
34% vs 45%

50 past situations · 50 companies · 31 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
JUBLFOOD
Consumer Services		 May 2025 117x11% +33%−15% −36%
WESTLIFE
Consumer Services		 Sep 2023 131x15% +30%−6% −30%
TRENT
Retail Trade		 Sep 2023 166x12% +47%−4% +151%
TORNTPHARM
Health Technology		 Jan 2020 75x13% +6%−5% +13%
DEVYANI
Consumer Services		 Dec 2022 139x16% +10%−15% −16%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
HATSUN
Consumer Non-Durables		 Oct 2021 —12% +122%−10% −31%
CHALET
Consumer Services		 Feb 2025 190x10% −9%−28% −7%
SAPPHIRE
Consumer Services		 May 2023 199x9% +37%−3% −31%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: drawdown from 12-month high, 12-month momentum and ROCE. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to KRISHNA INSTITUTE OF MED SCI. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

TILAKNAGAR INDUSTRIESTI
Consumer Non-Durables
72%similar
promoter holdingROCE
JUBILANT FOODWORKSJUBLFOOD
Consumer Services
67%similar
revenue growthdebt/equity
RAMKRISHNA FORGINGSRKFORGE
Producer Manufacturing
65%similar
P/Erevenue
BIOCONBIOCON
Health Technology
62%similar
P/Eoperating margin
PHOENIX MILLSPHOENIXLTD
Finance
60%similar
revenuemarket cap
ASTER DM QUALITY CAREASTERDM
Health Services
78%similar
P/Eoperating margin
DR AGARWALS HEALTH CAREAGARWALEYE
Health Services
60%similar
promoter holdingP/E
HEALTHCARE GLOBAL ENTPHCG
Health Services
53%similar
volatilityoperating margin

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Nov '23

  1. JunPriceRegained the 2025-07 peak, 5 months after the low.
  2. JunPeer rankSlipped to the bottom quartile of Health Services on ROCE (from the 3rd quartile).
  3. MayPriceVolume reached 10.5x its 50-day median on 2026-05-11; price +8.4% that day.
  4. MarResultsYear-on-year EPS growth turned negative.
  5. MarPeer rankSlipped to the bottom quartile of Health Services on EPS growth (from the 3rd quartile).
  6. FebValuationP/E crossed above the 90th percentile of its own history to date (88.8x).
  7. FebPriceVolume reached 5.4x its 50-day median on 2026-02-09; price +8.7% that day.
  8. JanPriceFell 26% from the Jul 2025 peak to the Jan 2026 low.
Show 22 earlier events
  1. DecPeer rankSlipped to the 3rd quartile of Health Services on ROCE (from the 2nd quartile).
  2. SepPromoterPromoter holding fell 4.7 pts to 34.1%.
  3. SepPeer rankSlipped to the 3rd quartile of Health Services on operating margin (from the 2nd quartile).
  4. AugPriceVolume reached 5.4x its 50-day median on 2025-08-08; price -4.3% that day.
  5. JulValuationP/E crossed above the 90th percentile of its own history to date (78.2x).
  6. JunPeer rankMoved into the 2nd quartile of Health Services on EPS growth (from the 3rd quartile).
  7. JunDebtDebt / equity rose above 1.0x (1.20x).
  8. MarResultsYear-on-year EPS growth turned positive.
  9. MarValuationP/E crossed above the 90th percentile of its own history to date (73.5x).
  10. MarPeer rankSlipped to the 2nd quartile of Health Services on operating margin (from the top quartile).
  11. MarPriceVolume reached 6.3x its 50-day median on 2025-03-03; price -0.5% that day.
  12. DecPeer rankMoved into the 3rd quartile of Health Services on EPS growth (from the bottom quartile).
  13. NovPriceVolume reached 8.5x its 50-day median on 2024-11-11; price -1.3% that day.
  14. SepPeer rankMoved into the top quartile of Health Services on operating margin (from the 2nd quartile).
  15. SepPriceVolume reached 10.9x its 50-day median on 2024-09-12; price +2.6% that day.
  16. JunResultsYear-on-year EPS growth turned negative.
  17. JunValuationP/E crossed above the 90th percentile of its own history to date (53.7x).
  18. JunPeer rankSlipped to the 2nd quartile of Health Services on ROCE (from the top quartile).
  19. MayPriceVolume reached 9.0x its 50-day median on 2024-05-27; price -2.9% that day.
  20. FebValuationP/E crossed above the 90th percentile of its own history to date (53.7x).
  21. JanPriceVolume reached 6.8x its 50-day median on 2024-01-05; price +1.1% that day.
  22. NovPeer rankSlipped to the 3rd quartile of Health Services on EPS growth (from the 2nd quartile).

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history66 months · 2021-06 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-11142.9x₹4214 cr9.4%10.0%1.9x
2026-10139.0x₹4214 cr9.4%10.0%1.9x
2026-09147.8x₹4214 cr9.4%10.0%1.9x
2026-08125.5x₹3906 cr11.8%10.0%1.9x
2026-07133.7x₹3906 cr11.8%10.0%1.9x
2026-06135.3x₹3906 cr11.8%10.0%1.9x
2026-05101.2x₹3628 cr16.1%15.0%1.2x
2026-0488.9x₹3628 cr16.1%15.0%1.2x
2026-0382.9x₹3628 cr16.1%15.0%1.2x
2026-0288.8x₹3402 cr18.1%15.0%1.2x
2026-0172.0x₹3402 cr18.1%15.0%1.2x
2025-1272.5x₹3402 cr18.1%15.0%1.2x
2025-1172.9x₹3218 cr20.7%15.0%1.2x
2025-1076.7x₹3218 cr20.7%15.0%1.2x
2025-0974.5x₹3218 cr20.7%15.0%1.2x
2025-0875.4x₹3034 cr21.2%15.0%1.2x
2025-0778.3x₹3034 cr21.2%15.0%1.2x
2025-0670.2x₹3034 cr21.2%15.0%1.2x
2025-0578.6x₹2871 cr22.7%17.0%0.7x
2025-0475.5x₹2871 cr22.7%17.0%0.7x
2025-0373.5x₹2871 cr22.7%17.0%0.7x
2025-0262.9x₹2705 cr21.8%17.0%0.7x
2025-0173.6x₹2705 cr21.8%17.0%0.7x
2024-1272.2x₹2705 cr21.8%17.0%0.7x
2024-1174.6x₹2580 cr20.6%17.0%0.7x
2024-1069.0x₹2580 cr20.6%17.0%0.7x
2024-0970.4x₹2580 cr20.6%17.0%0.7x
2024-0865.2x₹2498 cr20.1%17.0%0.7x
2024-0755.3x₹2498 cr20.1%17.0%0.7x
2024-0653.7x₹2498 cr20.1%17.0%0.7x
2024-0543.4x₹2198 cr24.0%24.0%0.4x
2024-0448.4x₹2198 cr24.0%24.0%0.4x
2024-0349.0x₹2198 cr24.0%24.0%0.4x
2024-0253.7x₹2198 cr24.0%24.0%0.4x
2024-0150.8x₹2198 cr24.0%24.0%0.4x
2023-1247.1x₹2198 cr24.0%24.0%0.4x
2023-1146.5x₹2198 cr24.0%24.0%0.4x
2023-1044.9x₹2198 cr24.0%24.0%0.4x
2023-0947.0x₹2198 cr24.0%24.0%0.4x
2023-0847.5x₹2198 cr24.0%24.0%0.4x
2023-0745.5x₹2198 cr24.0%24.0%0.4x
2023-0642.5x₹2198 cr24.0%24.0%0.4x
2023-0539.0x₹1651 cr27.1%34.0%0.2x
2023-0436.3x₹1651 cr27.1%34.0%0.2x
2023-0333.7x₹1651 cr27.1%34.0%0.2x
2023-0232.3x₹1651 cr27.1%34.0%0.2x
2023-0136.2x₹1651 cr27.1%34.0%0.2x
2022-1237.2x₹1651 cr27.1%34.0%0.2x
2022-1136.0x₹1651 cr27.1%34.0%0.2x
2022-1035.7x₹1651 cr27.1%34.0%0.2x
2022-0936.4x₹1651 cr27.1%34.0%0.2x
2022-0828.9x₹1651 cr27.1%34.0%0.2x
2022-0729.9x₹1651 cr27.1%34.0%0.2x
2022-0628.5x₹1651 cr27.1%34.0%0.2x
2022-0550.5x₹1330 cr25.9%29.0%0.4x
2022-0451.6x₹1330 cr25.9%29.0%0.4x
2022-0353.3x₹1330 cr25.9%29.0%0.4x
2022-0248.9x₹1330 cr25.9%29.0%0.4x
2022-0151.9x₹1330 cr25.9%29.0%0.4x
2021-1254.9x₹1330 cr25.9%29.0%0.4x
2021-1147.8x₹1330 cr25.9%29.0%0.4x
2021-1043.0x₹1330 cr25.9%29.0%0.4x
2021-0947.1x₹1330 cr25.9%29.0%0.4x
2021-0849.5x₹1330 cr25.9%29.0%0.4x
2021-0746.5x₹1330 cr25.9%29.0%0.4x
2021-0636.5x₹1330 cr25.9%29.0%0.4x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback